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Abstract
Background: All clinical practice guidelines recommend thiazides as a first-choice drug for the
management of uncomplicated hypertension. Thiazides are also the lowest priced antihypertensive
drugs. Despite this, the use of thiazides is much lower than that of other drug-classes. We wanted
to estimate the potential for savings if thiazides were used as the first choice drug for the
management of uncomplicated hypertension.
Methods: For six countries (Canada, France, Germany, Norway, the UK and the US) we estimated
the number of people that are being treated for hypertension, and the proportion of them that are
suitable candidates for thiazide-therapy. By comparing this estimate with thiazide prescribing, we
calculated the number of people that could switch from more expensive medication to thiazides.
This enabled us to estimate the potential drug-cost savings. The analysis was based on findings from
epidemiological studies and drug trials, and data on sales and prescribing provided by IMS for the
year 2000.
Results: For Canada, France, Germany, Norway, the UK and the US the estimated potential annual
savings were US$13.8 million, US$37.4 million, US$72.2 million, US$10.7 million, US$119.7 million
and US$433.6 million, respectively.
Conclusions:
Millions of dollars could be saved each year if thiazides were prescribed for hypertension in place 
of more expensive drugs. Our calculations are based on conservative assumptions. The potential 
for savings is likely considerably higher and may be more than US$1 billion per year in the US.
Background
Systematic reviews of randomized controlled trials have
not demonstrated superiority for any class of antihyper-
tensive drug [1,2]. However, the prevention of cardiovas-
cular disease is better documented for some drug classes
than others [1]. The evidence that first line thiazides are
effective in reducing the risk of cardiovascular disease is
particularly strong [1,3]. These drugs are also among the
best tolerated antihypertensives [4]. In addition, thiazides
are by far the lowest priced antihypertensive drugs. Con-
sequently, all clinical practice guidelines recommend thi-
azides either as the only first choice drug for the
management of uncomplicated hypertension, or as one of
the first-line agents [5].
Yet, thiazides are prescribed less frequently than other
antihypertensives [6–9]. For instance, in Norway the cost
of bendroflumethiazide is 1/10 of that of amlodipine (a
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calcium channel blocker), which is one of the most expen-
sive drugs used in the management of elevated blood
pressure [10]. Despite its high cost, amlodipine is the best
selling antihypertensive drug in Norway both in terms of
cost and in terms of dosages [7]. Amlodipine has also
been the largest-selling antihypertensive drug worldwide
(US$3.4 billion in 2000) [11]. This achievement is partic-
ularly remarkable considering that evidence for the drug's
effectiveness in preventing cardiovascular disease has
been lacking. The low use of thiazides may be caused by
misconceptions concerning possible problems with the
use of thiazides and the extensive promotion of other
more expensive medications [12].
We wanted to estimate the potential for drug cost savings
if more rational prescribing practices were employed.
Rational prescribing would in this case mean using thi-
azides as the drug of choice in the management of hyper-
tension when there is not an indication for selecting an
alternative drug.
Methods
We compared the direct drug costs of current prescribing
of antihypertensive medication with the costs if thiazides
were selected as the first choice drug for the management
of hypertension. The analysis was done for six countries:
Canada, France, Germany, Norway, the UK and the US.
Based on the results of systematic reviews we assumed that
thiazides and other antihypertensives are equally effective
medication for uncomplicated hypertension with regards
to health outcomes [1,2]. Consequently, we performed a
cost-minimisation study where we calculated drug costs
associated with thiazide and non-thiazide treatment for
uncomplicated hypertension.
We calculated the potential for savings on direct drug
expenses from the perspective of drug-payers, using sales
values to calculate costs. We did not include value added
tax (VAT) in the drug prices because antihypertensives are
largely paid for by the public in the majority of the coun-
tries we studied. When drugs are reimbursed with public
funds, VAT simply represents a transfer of funds between
the reimbursing agency and the treasury, and not as such
a real cost to the public sector. All economic figures are
reported in US dollars for the year 2000. The price year
was 2000.
We used the "defined daily dose" (DDD) as a measure for
the assumed average dose used for each drug [13]. The
DDD is recommended by The World Health Organization
as a standard measure for use in drug utilization studies
[14]. By convention, we expressed consumption of drugs
as DDDs/1000 inhabitants/day, which may serve as an
estimation of the proportion of the population receiving
the drug treatment. An estimated consumption of 10
DDDs/1000 inhabitants/day corresponds to a daily use of
1% of the population.
Potential use of thiazides for the management of 
hypertension
The starting point for the analysis was the proportion of
the total population currently on medication for hyper-
tension. We assumed that patients with hypertension
complicated by cardiovascular diseases should not use
thiazides and that only a proportion of those remaining
would be suitable candidates for thiazide-therapy, e.g.
due to adverse effects. We searched MEDLINE for the fol-
lowing estimates:
• The proportion of the population on medication for
hypertension
• The proportion of people on medication for hyperten-
sion that have additional cardiovascular disease
• The proportion of people with uncomplicated hyperten-
sion that can use thiazides
We found survey-based estimates of the proportion of the
population treated for hypertension in Canada (1986–
1992), England (1998), Norway (mid-90s), and the US
(1988–1994) [15–18]. For Germany and France we used
the lowest estimate (Canada). The surveys included only
parts of the adult population. In order to convert the sur-
vey findings to estimates for the total population, we used
demographic data from the International Data Base of the
US Census Bureau http://www.census.gov/ipc/www/idb
print.html.
Our search did not identify robust data on the proportion
of persons being treated for hypertension that have addi-
tional cardiovascular disease. A study from Finland
reported that 41% of those who were treated for hyperten-
sion also suffered from "other cardiovascular diseases"
[19]. Thirty-six percent of those taking medication for
hypertension in the Tromso study reported having had
angina, a heart attack or a stroke (E. Arnesen, personal
communication). Based on this, we assumed that 60% of
those being treated for hypertension do not have cardio-
vascular disease. This figure was applied to all six coun-
tries included in our analysis.
Rates of adherence to thiazide therapy ranged from 67%
to 87% in the randomized controlled trials we identified
reporting such rates [20–24]. Thus, we assumed that for
75% of people with uncomplicated hypertension, thi-
azides should be an appropriate drug, either as mono-
therapy or combined with other drugs. Consequently,BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/18
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Table 1: Current use and sales of anthypertensive drugs (based on IMS-data for the year 2000)
Total use (DDDs*/1000 
inhabitants/day)
Total sales (in US$1000, ex-
manufacturer)
Average price per DDD* Proportion for 
hypertension
Canada
Alpha blocking agents 3.6 18 744 $0.46 45 %
Thiazides 26.8 13 406 $0.04 87 %
Beta blocking agents 21.9 88 518 $0.35 52 %
Calcium channel blockers 39.2 265 497 $0.59 71 %
ACE-inhibitors‡ 58.0 279  688 $0.42 73  %
Angiotensin II antagonists‡ 10.6  69 055 $0.57 90 %
Total 160.1 734 908
France
Alpha blocking agents 4.3 60 815 $0.65 74 %
Thiazides 9.9 55 224 $0.26 90 %
Beta blocking agents 41.7 203 074 $0.22 67 %
Calcium channel blockers 38.2 297 152 $0.36 72 %
ACE-inhibitors ‡ 35.0 276 846 $0.37 75 %
Angiotensin II antagonists ‡ 15.2 178 691 $0.54 92 %
Total 144.3 1 071 802
Germany
Alpha blocking agents 5.0 84 900 $0.56 74 %
Thiazides 23.3 72 444 $0.10 54 %
Beta blocking agents 40.6 350 569 $0.29 66 %
Calcium channel blockers 48.4 365 760 $0.25 62 %
ACE-inhibitors ‡ 47.7 307 873 $0.21 75 %
Angiotensin II antagonists ‡ 13.1 182 211 $0.46 87 %
Total 178.1 1 363 757
Norway
Alpha blocking agents 10.5 7 590 $0.44 89 %†
Thiazides 9.1 620 $0.04 79 %†
Beta blocking agents 32.6 16 528 $0.31 50 %†
Calcium channel blockers 50.4 26 753 $0.32 60 %†
ACE-inhibitors‡ 35.0  17 997 $0.31 65 %†
Angiotensin II antagonists‡ 15.6  14 067 $0.55 90 %†
Total 153.2 83 555
UK
Alpha blocking agents 6.1 112 562 $0.85 64 %
Thiazides 38.8 51 135 $0.06 69 %
Beta blocking agents 28.7 165 872 $0.27 47 %
Calcium channel blockers 46.6 410 793 $0.41 55 %
ACE-inhibitors ‡ 42.6 355 284 $0.38 56 %
Angiotensin II antagonists ‡ 6.1 105 237 $0.79 65 %
Total 168.9 1 200 883
USA
Alpha blocking agents 11.6 702 423 $0.59 48 %
Thiazides 32.8 293 894 $0.09 81 %
Beta blocking agents 25.4 1 464 213 $0.56 53 %
Calcium channel blockers 57.5 4 302 075 $0.73 76 %
ACE-inhibitors ‡ 73.2 3 345 469 $0.44 74 %
Angiotensin II antagonists ‡ 12.7 1 001 629 $0.77 85 %
Total 213.2 11 109 703
*Defined daily dosages; †Based on data from 1994–96; ‡ Combinations with thiazides not includedBMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/18
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thiazides should be appropriate therapy for 45% (75% of
60%) of all on medication for hypertension.
Based on these estimates we calculated the potential use
of thiazides for the management of uncomplicated hyper-
tension for the total population in each country.
Current use of thiazides and non-thiazides for the 
management of hypertension
We estimated current use of antihypertensive drugs based
on country-specific data on sales and prescribing for the
year 2000, provided by IMS, a health research company.
IMS supplied us with figures of purchases made by retail
pharmacies and, where appropriate, other distribution
channels, such as mail order in the US. The prices that
were available in the IMS statistics were those demanded
by the manufacturer of the drugs and did not include mar-
gins added by wholesalers and retailers or VAT.
Estimates for the proportions of prescriptions for each
drug class that are made specifically for hypertension were
obtained from IMS' Medical Audit, which collects a repre-
sentative sample of prescriptions issued by primary care
physicians. We assumed that prescriptions made for
hypertension were, on average, of the same drug-quantity
as prescriptions made for other disorders. Prescribing data
for Norway were obtained from a prescription database
for 1994–96 (Norwegian Medicinal Depot, Oslo).
In the thiazide-group we also included non-thiazide low-
ceiling diuretics, such as chlorthalidone, and combined
formulations with potassium or a potassium-sparing
agent. The non-thiazide group consisted of alpha-block-
ing agents, beta-blocking agents, calcium channel block-
ers, ACE-inhibitors, and angiotensin II antagonists. ACE-
inhibitors and angiotensin II antagonists are available in
combination with a thiazide. These drugs were not
included in our analysis, either as thiazides or as drugs
that could be replaced by thiazides.
IMS files provided figures on drug consumption expressed
in kilograms. These were converted to DDDs/1000 inhab-
itants/day for each drug class, by using DDDs for each
drug and demographic data from the International Data
Base of the US Census Bureau. Figures on the current use
and sales of the various antihypertensive drug classes are
found in table 1.
Potential savings
The difference between potential and current use of thi-
azides for hypertension gave us the potential increase. We
assumed that an increase in the use of thiazides would
result in an equivalent decrease in the use of non-thiazide
antihypertensive drugs, expressed as dosages (DDDs).
Thus, one DDD of a thiazide was considered to be as effec-
tive as one DDD of any other antihypertensive drug. Prag-
matically, we assumed that a switch to thiazides would
mean that the reduction in use of non-thiazides would be
evenly distributed among the various drug-classes, in pro-
portion with their current use.
After calculating the current (2000) cost of non-thiazide
drugs for the management of uncomplicated hyperten-
sion we calculated the potential savings on these drugs by
multiplying the current costs with the potential percent
reduction. Similarly, we calculated the additional cost of
an increase in the use of thiazides. These calculations are
summarized mathematically in Appendix - see Additional
file: 1.
Sensitivity analyses
Our primary analysis was based on what we considered to
be either the best estimate or, if data were lacking, a con-
servative estimate for each variable. We carried out sensi-
tivity analyses to test the robustness of our findings. The
ranges for these analyses were, as far as possible, based on
empirical data.
Our estimates of the number of people using medication
for the management of hypertension are probably low for
several countries. In Norway the sales of antihypertensive
drugs have increased by almost 50% since the survey we
used in our main analysis was conducted in the mid-90s
[7,25]. This may partly be due to an increase in the use of
the drugs for other conditions, such as congestive heart
failure, but it is likely that the number of people treated
for hypertension has increased as well. The estimate from
the English health survey is the most recent and up to 50%
higher than the other estimates. We therefore used the
English estimate for the sensitivity analysis.
In the primary analysis we assumed that patients with car-
diovascular disease would not use thiazides for the
management of hypertension. However, 37% to 52% of
patients that take medication for hypertension report
using more than one antihypertensive drug [17,19,26],
and thiazides would be an appropriate second choice for
many that have cardiovascular disease. Thus, in the sensi-
tivity analysis we entered the assumption that 40% of
such patients could use thiazides.
Our assumption that 40% of those treated for hyperten-
sion have additional cardiovascular disease may be ques-
tioned due to the weak data we found for this estimate.
We considered 30% and 50% to be reasonable alternative
estimates to use in the sensitivity analysis, although we
have no solid basis for this.
We calculated the impact of adjusting the assumption that
75% of people with uncomplicated hypertension couldBMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/18
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use thiazides. We selected 65% and 85% as the range,
based on rates of adherence to therapy in randomized
controlled trials (67% to 87%) [20–24].
Alternative data-source for Norway
For Norway we also carried out our analysis substituting
the IMS figures with official sales figures. Norwegian sales
figures for medicines (quantity and expenditure) are avail-
able from official sales statistics and provide the price of
drugs to consumers.
Results
The potential increase in use of thiazides for the manage-
ment of hypertension (the difference between the poten-
tial and current use) is found in table 2. Total use of non-
thiazide antihypertensive drugs, excluding combination
drugs, is found in table 3. The potential decrease in use of
non-thiazides (table 3) corresponds to the potential
increase in use of thiazides (table 2).
The current (2000) total costs of thiazide and non-thi-
azide antihypertensive drugs for the management of
hypertension are given in table 4, along with the corre-
sponding potential increase and decrease in expenditures,
and the resulting net potential for direct drug-cost savings.
Sensitivity analyses
The results of the univariate sensitivity analyses are given
in table 5.
As described in the methods section, the values we have
used in our main analysis are most likely too low for two
of the variables: the proportion of the population treated
for hypertension and the proportion that could take thi-
azides among those with hypertension and cardiovascular
disease. For the remaining variables we have little reason
to believe that the values are either too low or too high. In
order to arrive at a best estimate for the potential savings,
we performed a sensitivity analysis in which we combined
the adjusted values for the two variables that we had rea-
son to believe that the values used in the main analysis
were low. The resulting potential savings are found in
table 6.
Alternative data-source for Norway
For Norway, the only country for which we have retail
data, the estimated potential savings were 15% higher
based on retail costs (excluding VAT) compared with
prices charged by manufacturers.
Table 2: Current and potential use of thiazides for hypertension
Proportion of the population on 
medication for hypertension*
Potential use of thiazides 
(DDDs/1000 inhabitants/day)†
Current use of thiazides 
(DDDs/1000 inhabitants/day)‡
Potential increase (DDDs/1000 
inhabitants/day)
Canada 5.8% 26.1 23.3 2.8 (12%)
France 5.8% 26.1 8.9 17.2 (193%)
Germany 5.8% 26.1 12.6 13.5 (107%)
Norway 6.1% 27.5 7.2 20.3 (282%)
UK 9.4% 42.2 26.8 15.4 (58%)
US 7.8% 35.0 26.6 8.4 (32%)
*Based on surveys for Canada, Norway, the UK and the US. Lowest estimate (Canadian) used for France and Germany †Assuming that a daily 
defined dose (DDD) of thiazide is appropriate medication for 45% of persons on medication for hypertension ‡Calculated from country-specific 
IMS-data for the year 2000
Table 3: Current and potential use of non-thiazides for hypertension
Current use of non-thiazides (DDDs/
1000 inhabitants/day)*
Potential decrease (DDDs/1000 
inhabitants/day)†
Canada 92.7 2.8 (3%)
France 98.9 17.2 (17%)
Germany 107.7 13.5 (13%)
Norway 92.7 20.3 (22%)
UK 70.8 15.4 (22%)
US 127.7 8.4 (7%)
* Calculated from country-specific IMS-data for the year 2000. Combination drugs are not included † Corresponding to the potential increase in use 
of thiazides (table 2)BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/18
Page 6 of 9
(page number not for citation purposes)
Discussion
Our analysis indicates that there is a substantial potential
for savings if thiazides were used as first-choice drugs in
the treatment of uncomplicated hypertension. We have
consistently used conservative assumptions. Sensitivity
analyses indicate that the true potential savings are likely
to be considerably higher than in our primary analyses for
all six countries. In the US, for instance, the potential drug
cost savings may be over US$1 billion.
The sales-figures we have used are based on the estimated
prices charged by manufacturers, which do not include
margins added by wholesalers and retailers. These mar-
gins are likely to vary between countries but not including
them is likely to have contributed to an underestimation
of the potential savings, as we have shown for Norway.
Not including VAT may also have resulted in underesti-
mates of the potential savings in countries where private
parties pay for drugs.
We may have overestimated the potential savings by not
taking into consideration specific recommendations
made for patients with diabetes and hypertension. How-
ever, thiazides are recommended as first-choice drug also
for this patient-group, except in the presence of diabetic
nephropathy [27]. Also, treatment goals for blood pres-
sure are usually set lower for patients with diabetes. Thus,
a particularly large proportion of these patients will
probably use more than one antihypertensive drug and a
thiazide would be an appropriate second drug in most
cases, if not selected as the primary agent.
We did not include any cost implications in our main
analysis other than a change in drug expenditures. There
are other costs related to antihypertensive therapy, such as
consultations, travel-expenses and laboratory tests.
However, we have little reason to believe that these costs
are significantly different for thiazides than for other
drugs. This assumption may be challenged by the fact that
Table 4: Current annual spending and potential for savings on drugs for the treatment of hypertension
Current spending on 
thiazides*
Potential increased 
spending on 
thiazides†
Current spending on 
non-thiazides*
Potential decreased 
spending on non-
thiazides‡
Resulting potential 
savings (per 
inhabitant)
Canada $11.7 million $1.4 million (12%) $509.3 million $15.2 million (3%) $13.8 million ($0.44)
France $49.7 million $95.8 million (193%) $767.0 million $133.2 million (17%) $37.4 million ($0.63)
Germany $39.1 million $42.0 million (107%) $910.4 million $114.1 million (13%) $72.2 million ($0.87)
Norway $0.5 million $1.4 million (282%) $55.4 million $12.1 million (22%) $10.7 million ($2.40)
UK $35.3 million $20.3 million (58%) $643.3 million $140.0 million (22%) $119.7 million ($2.01)
US $238.1 million $75.6 million (32%) $7 709.8 million $509.1 million (7%) $433.6 million ($1.57)
* Calculated from country-specific IMS-data for the year 2000. Combination drugs are not included † See table 2 ‡ See table 3
Table 5: Univariate sensitivity analyses
Potential savings (per inhabitant)
Main 
scenario
Proportion of the 
population 
treated for 
hypertension 
increased to 9.4%
Proportion of 
patients with 
hypertension and 
CVD* that can 
take thiazides 
increased from 
0% to 40%
Proportion of 
persons treated 
for hypertension 
that have CVD* 
increased from 
40% to 50%
Proportion of 
persons treated for 
hypertension that 
have CVD* 
decreased from 
40% to 30%
Proportion of 
persons with 
uncomplicated 
hypertension that 
can use thiazides 
decreased from 
75% to 65%
Proportion of 
persons with 
uncomplicated 
hypertension that 
can use thiazides 
increased from 75% 
to 85%
Canada $13.8 million 
($0.44)
$94.8 million 
($3.03)
$45.6 million 
($1.46)
$-7.9 million ($-
0.25)
$35.5 million ($1.14) $-3.6 million ($-0.11) $31.2 million ($1.00)
France $37.4 million 
($0.63)
$72.8 million 
($1.23)
$51.4 million 
($0.87)
$28.0 million 
($0.47)
$46.9 million ($0.79) $29.9 million ($0.50) $45.0 million ($0.76)
Germany $72.2 million 
($0.87)
$158.9 million 
($1.92)
$106.3 million 
($1.28)
$48.9 million 
($0.59)
$95.4 million ($1.15) $53.6 million ($0.65) $90.8 million ($1.10)
Norway $10.7 million 
($2.40)
$18.6 million 
($4.15)
$14.3 million 
($3.19)
$8.3 million 
($1.86)
$13.2 million ($2.94) $8.8 million ($1.96) $12.7 million ($2.83)
UK $119.7 million 
($2.01)
$119.7 million 
($2.01)
$199.8 million 
($3.36)
$65.1 million 
($1.09)
$174.3 million ($2.93) $76.0 million ($1.28) $163.4 million ($2.75)
US $433.6 million 
($1.57)
$808.9 million 
($2.94)
$873.5 million 
($3.17)
$133.6 million 
($0.49)
$733.5 million ($2.66) $193.6 million ($0.70) $673.5 million ($2.44)
*cardiovascular diseaseBMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/18
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thiazide use can lead to hypokalemia and measuring the
level of potassium one to two months after initiating treat-
ment may be advisable [4]. This could be an increased
cost of prescribing thiazides compared to other drugs.
However, we believe that this is of minor importance
since laboratory analyses are commonly undertaken as
part of evaluation and follow-up of hypertension therapy
in general.
We have strong reason to believe that health outcomes for
the treatment of uncomplicated hypertension are similar
for thiazides and other drugs [1,2], thus we can assume no
differences in indirect costs related to morbidity, such as
increased use of health services or reduced productivity
for patients. This can be questioned in light of the findings
of a recent trial where ACE-inhibitor based therapy pro-
duced better outcomes than diuretics, particularly in
elderly men [28]. On the other hand, in a newly published
meta-analysis involving all major randomised controlled
trials of antihypertensive medication the conclusion was:
"Low-dose diuretics are the most effective first-line treat-
ment" [29]. An additional point to be made from the
results of this meta-analysis is that thiazides tend to be
more effective at lowering blood pressure than other
agents. This suggests that increased use of thiazides might
reduce the need for additional medication and conse-
quently lead to even greater savings.
Interestingly, sales figures for thiazides are considerably
lower in Norway than in other countries. The level of thi-
azide use (DDDs/1000 inhabitants/day) varies widely
also within the Nordic countries. Compared to Norway,
the total use of thiazides is two, 3.5 and five times higher
in Sweden, Finland and Denmark respectively [8]. If Nor-
wegian physicians prescribed thiazides as frequently as
Danish physicians, the yearly savings for antihyperten-
sives would be about twice our estimated potential for
savings, suggesting, again, that our estimate is
conservative.
So far as we are aware, the potential savings has not been
quantified for the six countries we have considered. Nel-
son and colleagues studied the cost implications of actual
and recommended prescribing patterns for the manage-
ment of hypertension in Australia and estimated potential
savings for 1998 to be between $1.20 and $2.80 per
inhabitant [9].
Conclusions
There is increasing pressure to contain healthcare budgets
and increasing proportions of healthcare budgets are used
for prescription drugs. A yearly unnecessary expense of
millions of dollars is clearly undesirable. This could be
addressed in at least two ways: changing prescribing
practices among physicians or paying competitive prices
for equally effective antihypertensive drugs. Changing
prescribing practices, or professional practice in general, is
not easy [30]. It requires effective strategies and resources
to support these. In this case such an investment could
potentially save money and at the same time improve
quality, if it addressed other aspects of managing hyper-
tension, such as ensuring that the right people are started
on medication and once started blood pressure is lowered
to desired levels. Alternatively, drug purchasers could
refuse to pay non-competitive prices for drugs that do not
have any proven benefits over thiazides.
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